Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$5.69$13.89
1-Month Range
Month up 0.7%
$13.74$13.89
Daily Price Range
Day down -0.2%
$13.86$13.89
Volume
vs 2M avg
6340202M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$3.6B
Short % of Float—
Employees—
Sales$6,216M
Shares Outstanding262,621,584
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.ogn.com
Organon & Co — Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle sti….· via yahoo
Warnings
3 signals
Live
- Debt/Equity elevated at 717.0
- Negative revenue growth (-1.7%)
- Price 144% above 52-week low — momentum stretched
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
95
Growth
72
Quality
69
Sentiment
95
Insider Sent.
33
Piotroski F
6
Altman Z
1.1
Consensus rating unavailable — no analyst coverage on file for OGN.
Price targets unavailable — no 12-month targets on file for OGN.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on OGN, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 3 warnings surfacedNov 11, 2026, 6:08 PM UTC